ArticleInvestigational new drugs2006
Phase I study of vinflunine administered as a 10-minute infusion on days 1 and 8 every 3 weeks.
Article in Investigational new drugs, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 41 citations in OpenAlex.
- A phase II study of vinflunine in bladder cancer patients progressing after first-line platinum-containing regimen.British journal of cancer · 2006Trial
- Vinflunine in the treatment of advanced urothelial cancer: clinical evidence and experience.Therapeutic advances in urology · 2017Review
- Metastatic Bladder Cancer: Second-Line Treatment and Recommendations of the Genitourinary Tumor Division of the Galician Oncologic Society (SOG-GU).Current oncology reports · 2016Review
- How to manage intravenous vinflunine in cancer patients with renal impairment: results of a pharmacokinetic and tolerability phase I study.British journal of clinical pharmacology · 2014Article
- Cancer wars: natural products strike back.Frontiers in chemistry · 2014Review
- Phase I and pharmacokinetic study of IV vinflunine in cancer patients with liver dysfunction.Investigational new drugs · 2013Article
- Vinflunine.Drugs · 2010Review
- Critical evaluation of vinflunine in the treatment of refractory metastatic urothelial carcinoma.Open access journal of urology · 2010Review
- Vinflunine in the treatment of bladder cancer.Therapeutics and clinical risk management · 2008Article
- State-of-the-art management of metastatic disease at initial presentation or recurrence.World journal of urology · 2006Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 5 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Vinflunine is a novel vinca alkaloid developed through the selective modification of vinorelbine using super-acidic chemistry. In preclinical testing, vinflunine demonstrated significantly enhanced anti-tumour activity in human tumour xenograft models when compared to its parent compound. A phase I study was conducted to evaluate the safety and toxicity of vinflunine administered as a 10 minute intravenous infusion on days 1 and 8 every three weeks. Sixteen patients with advanced solid tumours were treated. Two of four patients experienced dose limiting toxicities (DLT) at 190 mg/m2 and this was established as the maximum tolerated dose (MTD). At the MTD, the DLT of vinflunine consisted of constipation and neutropenia. Fatigue was notable but not dose limiting. No objective responses were observed. A dose of 170 mg/m2 given on a day 1 and 8 schedule every three weeks would be suitable for future studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.